We spoke to new Sterling Energy CEO Tony Hawkins about the latest changes happening at the company. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,212.20
Bid: 1,212.20
Ask: 1,212.40
Change: -0.80 (-0.07%)
Spread: 0.20 (0.02%)
Open: 1,215.00
High: 1,220.40
Low: 1,204.80
Yest. Close: 1,213.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Wednesday preview: Glaxo, Next

Drugs giant GlaxoSmithKline issues third quarter figures on Wednesday with the market expecting revenue to decline but earnings to rise. Revenue is forecast to slide by around 5% to £6,758m from £7,104m the year before, but operating profit is seen climbing to £2,257m from £2,179m. Earnings per sh

30 Oct 12 15:59

Glaxo & Pfizer rejig JV deal with Shionogi

ViiV Healthcare, a joint venture (JV) between drugs giants GlaxoSmithKline and Pfizer, is to acquire the exclusive global rights to the assets of Shionogi-ViiV Healthcare, a JV set up with Shionogi, the Japanese pharmaceuticals firm. The assets include the investigational medicine dolutegravir and

29 Oct 12 07:09

Sunday newspaper round-up: Pearson, 40p tax, BAE

News Corporation has joined the race for Penguin with a last-minute overture to the directors of Pearson, the media conglomerate that owns the book publisher. Glen Moreno, Pearson's chairman, will put the approach to directors in the next few days. Rupert Murdoch, the chairman and chief executive of

28 Oct 12 19:28

Week ahead: Banking results and election fever to take centre-stage

Next week is set to be an extremely busy week, looking at the corporate and economic calendar from home and abroad. Third-quarter UK corporate earnings season really gets into full swing with some heavyweight Footsie constituents scheduled to report, including GlaxoSmithKline, Shell, Smith & Nephew

26 Oct 12 09:08

FTSE 100 movers: Burberry rises on signs of improved trading

Shares in stock market darling Burberry, the luxury fashion chain, leapt on Thursday, after it said its situation had started to improve towards the end of the July-September quarter, during which time sales growth in its stores slowed dramatically, as expected. LFL sales over the half-year were u

11 Oct 12 15:35

London close: Stocks end flat after BoE and ECB decisions

- BoE and ECB hold rates - US data beats estimates - Next leads risers after broker comments The Footsie swung between gains and losses for most of Thursday's session but finished the day broadly flat following a busy day on the global economic calendar, which saw policy decisions in the UK and Eur

4 Oct 12 17:02

London midday: Stocks edge higher as BoE holds rates

- Middle-East tensions dampen sentiment - BoE holds rates; ECB decision eyed - Investors await US jobless claims After swinging into negative territory briefly, the FTSE 100 was back above water by Thursday lunchtime ahead of interest rate decisions in the UK and Europe. Meanwhile, investors were s

4 Oct 12 11:47

London open: Stocks gain ahead of central bank announcements

- Investors await BoE and ECB decisions, FOMC minutes - Tate & Lyle jumps after Credit Suisse upgrades - Halfords appoints new CEO after strong Q2 European stock markets have opened with moderate gains ahead of what is likely to be a busy day on the economic front, with rate decisions due out from

4 Oct 12 08:23

Glaxo's HIV drug a step closer to regulatory submission

Pharmaceuticals behemoth GlaxoSmithKline said its joint venture company, Shionogi-ViiV Healthcare, has completed an initial clinical registration package for dolutegravir, its treatment for HIV patients. Phase III data required for initial regulatory filings for dolutegravir to be used on adults in

4 Oct 12 07:25

FTSE 100 movers: BAE drops on broker notes

Defence group BAE Systems was also a heavy faller, pulling back after surging yesterday on discussions with aerospace giant EADS regarding a "possible combination" of the businesses. Investec, Societe Generale and Oriel Securities cut their recommendations for the stock this morning. Hot on its hee

13 Sep 12 14:56

GlaxoSmithKline increases stake in Response Genetics

Pharmaceuticals giant GlaxoSmithKline (GSK) has acquired five million newly-issued shares in Response Genetics, taking its stake in the company to around 15.2 per cent. GSK purchased the shares at 110 cents each in cash. "This transaction builds on the relationship GSK and Response Genetics have

13 Sep 12 14:43

Wednesday broker round-up

AMEC: Nomura retains buy rating and 1,240p target. Ashtead: UBS ups target from 340p to 375p, buy rating unchanged. ASOS: Oriel Securities upgrades to buy; BarCap upgrades to overweight, target lifted rom 1,800p to 2,400p. BP: Investec keeps buy rating and 460p target. BT Group: JPMorgan Cazenov

5 Sep 12 09:20

London close: Footsie finishes flat after long weekend

- Markets await Jackson Hole symposium - Miners lower on concerns over Japan - Chemring drops after profit warning. Concerns about global economic growth were weighing on sentiment on Tuesday, meaning that the FTSE 100 was little changed by the close despite some volatile swings between gains and

28 Aug 12 16:48

London midday: Stocks erase losses after Spanish auction

- Spanish bond auction lifts sentiment - Miners lower on concerns over Japan - Chemring drops profit warning. London's blue-chip index was trading broadly flat by midday, having erased all of the morning's losses, after a solid Spanish bond auction eased concerns about the heavily indebted Eurozone

28 Aug 12 11:47

Broker tips: Glaxo, Bunzl, Ophir Energy

UBS has lowered its recommendation for pharmaceuticals giant GlaxoSmithKline from 'buy' to 'neutral', saying that there's limited potential for further upside. "Given GSK's valuation, and somewhat reduced earnings visibility for the stock, we see less scope for performance versus peers, and thereby

28 Aug 12 11:17

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.